Literature DB >> 3834066

Analysis of pharmacokinetic data using parametric models. II. Point estimates of an individual's parameters.

L B Sheiner.   

Abstract

This is the second in a series of tutorial articles discussing the analysis of pharmacokinetic data using parametric models. In this article the basic issue is how to estimate the parameters of such models. Primary emphasis is placed on point estimates of the parameters of the structural (pharmacokinetic) model. All the estimation methods discussed are least squares (LS) methods: ordinary least squares, weighted least squares, iteratively reweighted least squares, and extended least squares. The choice of LS method depends on the variance model. Some discussion is also provided of computer methods used to find the LS estimates, identifiability, and robust LS-based estimation methods.

Mesh:

Substances:

Year:  1985        PMID: 3834066     DOI: 10.1007/bf01059333

Source DB:  PubMed          Journal:  J Pharmacokinet Biopharm        ISSN: 0090-466X


  11 in total

1.  Forecasting individual pharmacokinetics.

Authors:  L B Sheiner; S Beal; B Rosenberg; V V Marathe
Journal:  Clin Pharmacol Ther       Date:  1979-09       Impact factor: 6.875

Review 2.  Computers, models, and optimization in physiological kinetics.

Authors:  L E Johnson
Journal:  CRC Crit Rev Bioeng       Date:  1974-02

3.  General treatment of linear mammillary models with elimination from any compartment as used in pharmacokinetics.

Authors:  L Z Benet
Journal:  J Pharm Sci       Date:  1972-04       Impact factor: 3.534

4.  Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1983-06

5.  Analysis of pharmacokinetic data using parametric models--1: Regression models.

Authors:  L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1984-02

6.  Alternative approaches to estimation of population pharmacokinetic parameters: comparison with the nonlinear mixed-effect model.

Authors:  J L Steimer; A Mallet; J L Golmard; J F Boisvieux
Journal:  Drug Metab Rev       Date:  1984       Impact factor: 4.518

7.  Pharmacokinetic parameter estimates from several least squares procedures: superiority of extended least squares.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1985-04

8.  Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential model and experimental pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1981-10

9.  Parameter and structural identifiability concepts and ambiguities: a critical review and analysis.

Authors:  C Cobelli; J J DiStefano
Journal:  Am J Physiol       Date:  1980-07

10.  Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten model: routine clinical pharmacokinetic data.

Authors:  L B Sheiner; S L Beal
Journal:  J Pharmacokinet Biopharm       Date:  1980-12
View more
  15 in total

1.  Mathematical model for in vivo pharmacodynamics integrating fluctuation of the response: application to the prolactin suppressant effect of the dopaminomimetic drug DCN 203-922.

Authors:  P Francheteau; J L Steimer; C Dubray; D Lavene
Journal:  J Pharmacokinet Biopharm       Date:  1991-06

2.  Nonlinear kinetics of the thiamine cation in humans: saturation of nonrenal clearance and tubular reabsorption.

Authors:  W Weber; M Nitz; M Looby
Journal:  J Pharmacokinet Biopharm       Date:  1990-12

3.  A model with separate hepato-portal compartment ("first-pass" model): fitting to plasma concentration-time profiles in humans.

Authors:  V Piotrovskij; A Van Peer
Journal:  Pharm Res       Date:  1997-02       Impact factor: 4.200

Review 4.  Review of methods and criteria for the evaluation of bioequivalence studies.

Authors:  G Pabst; H Jaeger
Journal:  Eur J Clin Pharmacol       Date:  1990       Impact factor: 2.953

5.  Saturable rate of cefatrizine absorption after oral administration to humans.

Authors:  B G Reigner; W Couet; J P Guedes; J B Fourtillan; T N Tozer
Journal:  J Pharmacokinet Biopharm       Date:  1990-02

Review 6.  Adaptive control methods for the dose individualisation of anticancer agents.

Authors:  A Rousseau; P Marquet; J Debord; C Sabot; G Lachâtre
Journal:  Clin Pharmacokinet       Date:  2000-04       Impact factor: 6.447

7.  Analysis of pharmacokinetic data using parametric models. III. Hypothesis tests and confidence intervals.

Authors:  L B Sheiner
Journal:  J Pharmacokinet Biopharm       Date:  1986-10

8.  Plasma and red blood cell pharmacokinetics of pimobendan enantiomers in healthy Chinese.

Authors:  K M Chu; S M Shieh; O Y Hu
Journal:  Eur J Clin Pharmacol       Date:  1995       Impact factor: 2.953

9.  Application of optimal sampling theory to the determination of metacycline pharmacokinetic parameters: effect of model misspecification.

Authors:  M Tod; C Padoin; K Louchahi; B Moreau-Tod; O Petitjean; G Perret
Journal:  J Pharmacokinet Biopharm       Date:  1994-04

10.  Identification of patients with impaired hepatic drug metabolism using a limited sampling procedure for estimation of phenazone (antipyrine) pharmacokinetic parameters.

Authors:  D Fabre; F Bressolle; R Goméni; O Bouvet; A Dubois; C Raffanel; J C Gris; M Galtier
Journal:  Clin Pharmacokinet       Date:  1993-04       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.